Weekly CEO Buys Highlight

Details the CEO buys this past week for the following companies: Carriage Services, Cannae Holdings, Golub Capital BDC and Chinook Therapeutics

Author's Avatar
Dec 14, 2020
Article's Main Image

According to GuruFocus Insider Data, these were the largest CEO buys during the past week.

Carriage Services

Carriage Services Inc. (CSV, Financial) CEO Melvin C. Payne bought 29,000 shares on Dec. 9 at a price of $30.02. The price of the stock has decreased by 1.03% since then.

112961c05a5506725c4333511575bdd9.png

Carriage Services is a leading provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: the Funeral Home Operations segment, which offers burial, cremation, consultation and other services; and the Cemetery Operations segment, which provides services such as mausoleum crypts, private estates, lawn crypt gardens, traditional single burial gravesites and burial vaults.

The company has a market cap of $533.88 million. Its shares traded at $29.71 with a price-earnings ratio of 52.03 as of Dec. 11.

Net income for the third quarter of 2020 was $5.5 million.

Cannae Holdings

Cannae Holdings Inc. (CNNE, Financial) CEO Richard N. Massey bought 15,000 shares on Dec. 8 at a price of $42.33. Since then, the price of the stock has increased by 0.45%.

f1a39c38c8e0dd8686d7ae9e38918dfc.png

Cannae Holdings is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant group, Ceridian, T-System, Dun & Bradstreet, Corporate and other.

The company has a market cap of $3.90 billion. Its shares traded at $42.52 with a price-earnings ratio of 2.71 as of Dec. 11.

Net loss for the quarter ended Sept. 30, 2020 was $14.9 million.

Golub Capital BDC

Golub Capital BDC Inc. (GBDC, Financial) CEO David Golub bought 7,961 shares during the past week at the average price of $14.08.

bd60dfd223b314c745bf0d8be655bb4d.png

Golub Capital BDC is an externally managed, closed-end, non-diversified investment management company. The company's investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second lien and subordinated loans, warrants and minority equity securities in middle-market companies.

The company has a market cap of $2.3 billion. Its shares traded at $13.75 with a price-earnings ratio of 37.36 as of Dec. 11.

Net investment income during the three months ended Sept. 30 was $39.31 million.

Golub bought 4,000 shares on Nov. 27 at a price of $14.01; 3,755 shares on Dec. 1 at a price of $13.99; 4,000 shares on Dec. 2 at a price of $14.09; 3,961 shares on Dec. 7 at a price of $14.09; and 4,000 shares on Dec. 9 at a price of $14.08. The price of the stock has decreased by 2.34% since then.

Chairman Lawrence E. Golub bought 4,000 shares on Nov. 27 at a price of $14.01; 3,755 shares on Dec. 1 at a price of $13.99; 4,000 shares on Dec. 2 at a price of $14.09; 3,961 shares on Dec. 7 at a price of $14.09; and 4,000 shares on Dec. 9 at a price of $14.08. Since then, the price of the stock has decreased by 2.34%.

Chinook Therapeutics

Chinook Therapeutics Inc. (KDNY, Financial) President and CEO Eric Dobmeier bought 4,000 shares on Dec. 9 at a price of $13.16. The price of the stock has increased by 1.22% since then.

c53a123354926ffb69c87a4f7c64668c.png

Chinook Therapeutics is a clinical-stage biotechnology company. It is engaged in developing precision medicines for kidney diseases. The products of the company are focused on rare, severe chronic kidney disorders.

The company has a market cap of $561.55 million. Its shares traded at $13.32 as of Dec. 11.

Net loss for the third quarter of 2020 was $14.54 million.

Dobmeier also bought 2,000 shares on Nov. 23 at a price of $13.63. Since then, the price of the stock has decreased by 2.27%.

For the complete list of stocks bought by their company CEOs, go to: CEO Buys.

Disclosure: I do not own stock in any of the companies mentioned in the article.

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.